country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-A0117

Copy Link Print Information

Temocaprilat

(Synonyms: Temocapril diacid; Temocaprilate; RS 5139)

Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 110221-53-9
Formel: C₂₁H₂₄N₂O₅S₂
Molecular Weight:448.56

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (275 KB)

Temocaprilat Chemical Structure

CAS. Nr.: 110221-53-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Temocaprilat (1, 10, 100 and 1000 nM; 72 h) relieves high glucose (22.2 mM) mediated inhibition of human aortic endothelial cells (HAECs) proliferation with dose-dependent manner. Temocaprilat inhibits oxidative stress induced by high glucose in HAECs^[1].
Temocaprilat (1 µM; 10 min) increases protein kinase C (PKC) activity in HAECs^[1].
Temocaprilat (0.1 µM) inhibits IL-1β induced IL-6 expression by reducing the stability of IL-6 mRNA^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Temocaprilat (1 mg/kg/d; i.v.; 4 weeks) significantly reduces systolic blood pressure with time-dependent manner in spontaneously hypertensive (SHR) rats. Temocaprilat improves myocardial fibrosis and oxidative stress in Wistar-Kyoto (WKY) rats and SHR rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six 10-week-old WKYs and SHRs and six 50-week-old (aging control) SHRs^[3].
Dosage:

1 mg/kg/d.
Administration:

Intravenous injection; 4 weeks.
Result:

Reduced the expression levels of myocardial fibrosis, transforming growth factor-β1 (TGF-β1) mRNA and fibroblast growth factor-2 (FGF-2) mRNA in the left ventricle (LV).
Weakened the expression levels of 8-isoprostane, p22phox mRNA, p47phox mRNA and gp91phox mRNA in LV.

Chemical Information

CAS. Nr. 110221-53-9
Molecular Weight 448.56
Formel C₂₁H₂₄N₂O₅S₂
SMILES

OC(CN1C[C@@H](C2=CC=CS2)SC[C@@H](C1=O)N[C@H](C(O)=O)CCC3=CC=CC=C3)=O
Synonyms

Temocapril diacid; Temocaprilate; RS 5139
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yasunari K, et al. Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation. J Cardiovasc Pharmacol. 2003 Dec;42 Suppl 1:S55-60. [Content Brief]

[2]. Püchler K, et al. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br J Clin Pharmacol. 1998 Oct;46(4):363-7. [Content Brief]

[3]. Ito N, et al. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens. 2007 Jul;20(7):792-9. [Content Brief]

[4]. Yang Z H, et al. P-540: Olmesartan and temocaprilat suppress IL-1 [beta]-induced IL-6 expression via a decrease in mRNA stability in vascular smooth muscle cells[J]. American Journal of Hypertension, 2002, 15(S3): 228A.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen